HTG Molecular Diagnostics (HTGMQ) Stock Price, News & Analysis

Company Overview

HTG Molecular Diagnostics, Inc. (NASDAQ: HTGMQ) develops and commercializes molecular profiling solutions for clinical research and precision medicine applications. The company’s primary focus is on delivering sample-to-answer assays that streamline gene expression profiling, enabling high-throughput analysis of RNA and protein biomarkers. By leveraging its proprietary HTG EdgeSeq platform, HTG aims to simplify complex workflows and reduce hands-on time compared to traditional next-generation sequencing (NGS) methods.

The HTG EdgeSeq technology integrates microfluidic processing with NGS, allowing for direct interrogation of formalin-fixed, paraffin-embedded (FFPE) tissue and protein lysates without requiring separate RNA extraction or library preparation steps. Key products include the EdgeSeq Oncology Biomarker Panel, designed to profile hundreds of cancer-related genes, and the EdgeSeq Immuno-Oncology Assay, which targets immune-related gene signatures. These assays support biomarker discovery, translational research and companion diagnostic development in oncology, immunology and other therapeutic areas.

Headquartered in Tucson, Arizona, HTG serves a global customer base encompassing pharmaceutical and biotechnology companies, academic research centers, and clinical reference laboratories. The company’s offerings are utilized in preclinical studies and clinical trials to facilitate drug candidate selection, patient stratification and evaluation of treatment response. HTG’s commercial strategy combines direct sales in North America with distribution partnerships in Europe, Asia and other international markets.

Since its founding, HTG Molecular Diagnostics has emphasized innovation in molecular diagnostic workflows to accelerate precision medicine. The company’s leadership prioritizes comprehensive assay performance, operational efficiency and collaboration with research and clinical partners. Through its EdgeSeq platform and assay portfolio, HTG continues to advance tools that empower scientists and clinicians to uncover critical insights into disease biology and support the development of targeted therapeutic approaches.

Key Stats

• Today's Range: $0.0001 to $0.0001
• 50-Day Range: N/A
• 52-Week Range: $0.0001 to $0.01
• Volume: 209 shs
• Average Volume: 1,577 shs
• Market Capitalization: $221.00
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

HTGMQ Stock Analysis - Frequently Asked Questions

How have HTGMQ shares performed this year?

HTG Molecular Diagnostics' stock was trading at $0.0001 at the beginning of 2025. Since then, HTGMQ shares have increased by 0.0% and is now trading at $0.0001.

How do I buy shares of HTG Molecular Diagnostics?

Shares of HTGMQ stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

• Today: 9/25/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Analytical instruments
• Sub-Industry: Measuring And Control Equipment
• Current Symbol: NASDAQ:HTGMQ
• CIK: 1169987
• Web: www.htgmolecular.com
• Phone: 877-289-2615
• Fax: 520-547-2837
• Employees: 90
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: $6.37 million
• Price / Sales: 0.00
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 2,210,000
• Free Float: 2,156,000
• Market Cap: $221.00
• Optionable: Not Optionable
• Beta: 3.02